Abstract | STUDY OBJECTIVES: PATIENTS AND METHODS: Eighteen patients with stable chronic heart failure were administered perindopril, 4 mg/d, in addition to their standard therapy for a period of 6 months. Fourteen patients completed the study. Maximum inspiratory pressure (PImax) and maximum expiratory pressure (PEmax) expressed in percentage of predicted values, left ventricular ejection fraction (LVEF) determined by means of two-dimensional echocardiography, and pulmonary volumes were obtained before and after therapy. MEASUREMENTS AND RESULTS: As compared to baseline, there was a significant increase in both PImax and PEmax after therapy (57 +/- 27% predicted vs 78 +/- 36% predicted and 62 +/- 20% predicted vs 73 +/- 15% predicted, respectively; each p < 0.05). LVEF increased (34 +/- 5% vs 41 +/- 10%; p < 0.05); functional class improved by > or = 1 New York Heart Association (NYHA) class in five patients. There were no changes in pulmonary volumes. No correlation was found between changes in PImax and PEmax and changes in either LVEF or NYHA functional class. CONCLUSIONS:
|
Authors | C Coirault, A Hagège, D Chemla, M D Fratacci, C Guérot, Y Lecarpentier |
Journal | Chest
(Chest)
Vol. 119
Issue 6
Pg. 1755-60
(Jun 2001)
ISSN: 0012-3692 [Print] United States |
PMID | 11399702
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Perindopril
|
Topics |
- Angiotensin-Converting Enzyme Inhibitors
(administration & dosage, therapeutic use)
- Chronic Disease
- Echocardiography
- Female
- Heart Failure
(drug therapy, physiopathology)
- Humans
- Male
- Middle Aged
- Perindopril
(administration & dosage, therapeutic use)
- Prospective Studies
- Respiratory Muscles
(drug effects, physiology)
- Stroke Volume
(drug effects)
|